PC, DABR, FASLMS
Director, Bard Cancer Diagnostics
Robert L. Bard is an internationally recognized leader in the field of 21st century 3D Ultrasonographic Volumetric Doppler Imaging. Dr. Bard specializes in advanced 3D sonography to detect cancers in numerous organs including the breast, prostate, skin, thyroid, melanoma and other areas. The images are used to accurately guide biopsies, target therapy and provide focused follow-up after treatment. Dr. Bard’s medical career began as a diagnostic radiologist and evolved into the practice of non-invasive 3D imaging with ultrasound, MRI and laser technologies. He has been the head radiologist at several leading hospitals and published a multitude of textbooks and scientific papers. He presents articles worldwide, teaches at international conferences and is on the Editorial Review Board of national and international medical journals. Dr. Bard holds medical licenses in several states, as well as Board certification from the American Board of Radiology (1974) and Fellowship in the American Society of Lasers in Medicine and Surgery (2014).
Dr. Bard currently runs a private consulting practice in New York City and is the Director of Bard Cancer Diagnostics. In 2018, after a news report about 15 cases from 9/11 first responders, Dr. Bard launched the first official male-dedicated (and “male-friendly”) imaging and analysis program of its kind to support the growing male breast cancer cases in the Northeast. The program was formed as part of a joint task force for public awareness and a dedicated male-breast screening program to help address this gender-specific health threat. His design for male breast cancer screening meant a special calibration of imaging paradigm to identify and pre-determine traces of IDC invasive ductal carcinoma and other malignancies in the tissues of the male breast often found in specific areas by studying the behavior of the tumor vascular flow under the skin. The program also addresses continued monitoring for recurrence prevention (which has been reported in a significant percentage of male breast cancer cases).” In the past few years, Dr. Bard has used his 3D Doppler Imaging procedure to detect breast cancer in a number of men, including several 9/11 first responders.
In his role as Director of Bard Cancer Diagnostics, he regularly lectures at Mt. Sinai Medical Center, NYU Medical Center and leading international hospitals in England, France, Spain and the Netherlands. He appears frequently on regional television, national radio and is a consultant to major healthcare organizations. He is committed to improving non-invasive cancer testing and developing minimally invasive image guided technologies to prevent cancer spread through his foundation, The Biofoundation for Angiogenesis Research and Development.